P-Gp Or Bcrp Substrates has 17 known drug interactions based on U.S. FDA drug labeling data. 8 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Adagrasib, Belumosudil, Berotralstat Hydrochloride. Patients taking P-Gp Or Bcrp Substrates should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 17
- Major
- 8
- Moderate
- 9
Major (8)
- P-Gp Or Bcrp Substrates + Adagrasib— Adagrasib increases exposure of P-gp substrates, which may increase the risk of adverse reactions where minimal concentr…
- P-Gp Or Bcrp Substrates + Belumosudil— Belumosudil affects P-gp substrates for which minimal concentration changes may lead to serious toxicities. Avoid concom…
- P-Gp Or Bcrp Substrates + Berotralstat Hydrochloride— P-gp inducers may decrease berotralstat plasma concentration, leading to reduced efficacy of ORLADEYO. Avoid concomitant…
- P-Gp Or Bcrp Substrates + Imlunestrant— Imlunestrant inhibits P-gp and BCRP, increasing substrate exposure and risk of adverse reactions. Avoid concomitant use …
- P-Gp Or Bcrp Substrates + Pazopanib— Coadministration may increase pazopanib concentrations. Avoid concomitant use.
- P-Gp Or Bcrp Substrates + Pralsetinib— Concomitant use increases pralsetinib exposure, which may increase the risk of adverse reactions. Avoid coadministration…
- P-Gp Or Bcrp Substrates + Repotrectinib— Concomitant use may increase repotrectinib exposure and increase incidence and severity of adverse reactions. Avoid conc…
- P-Gp Or Bcrp Substrates + Tucatinib— TUKYSA increases plasma concentrations of P-gp substrates, which may increase toxicity where minimal concentration chang…
Moderate (9)
- P-Gp Or Bcrp Substrates + Capmatinib— Coadministration increased P-gp substrate exposure, which may increase adverse reactions. Decrease substrate dosage if c…
- P-Gp Or Bcrp Substrates + Darunavir, Cobicistat, Emtricitabine, And Tenofovir Alafenamide— Co-administration may result in increased plasma concentrations of P-gp substrates due to transporter inhibition.
- P-Gp Or Bcrp Substrates + Elvitegravir, Cobicistat, Emtricitabine, And Tenofovir Alafenamide— P-gp inducers are expected to decrease absorption of TAF, resulting in decreased plasma concentration.
- P-Gp Or Bcrp Substrates + Levacetylleucine— Monitor more frequently for P-gp substrate related adverse reactions when used concomitantly with levacetylleucine. Leva…
- P-Gp Or Bcrp Substrates + Mavorixafor— Increase mavorixafor Cmax and AUC. Monitor for adverse reactions and reduce dosage by 100 mg steps if necessary, but not…
- P-Gp Or Bcrp Substrates + Mitapivat— Monitor patients for adverse reactions of substrates with narrow therapeutic index.
- P-Gp Or Bcrp Substrates + Selpercatinib— RETEVMO is a P-gp inhibitor; concomitant use increases substrate plasma concentrations. Avoid coadministration; if unavo…
- P-Gp Or Bcrp Substrates + Sparsentan— Monitor for adverse reactions of P-gp substrates with narrow therapeutic indices. Increased exposure to substrates.
- P-Gp Or Bcrp Substrates + Vanzacaftor, Tezacaftor, And Deutivacaftor— Monitor more frequently for adverse reactions. Tezacaftor and deutivacaftor are P-gp inhibitors that increase exposure o…